NCT00259363View on ClinicalTrials.gov

Oxaliplatin in Rectal Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2006

Conditions

Rectal Neoplasms

Interventions

DRUG

Oxaliplatin

oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days

Trial Locations (1)

Unknown

Sanofi-Aventis, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY